DT-DIAPHORASE ACTIVITY IN NORMAL AND NEOPLASTIC HUMAN TISSUES - AN INDICATOR FOR SENSITIVITY TO BIOREDUCTIVE AGENTS

E SMITSKAMPWILMS, G GIACCONE, HM PINEDO, B.F.A.M. VAN DER LAAN, GJ PETERS

Research output: Contribution to journalArticleAcademicpeer-review

65 Citations (Scopus)

Abstract

DT-diaphorase (DTD) is an important enzyme for the bioreductive activation of the new alkylating indoloquinone EO9. In preclinical studies, EO9 has shown selective anti-tumour activity against solid tumours and under hypoxic conditions. The levels of three reductive enzymes have been determined in three types of human solid tumours, together with corresponding normal tissues and normal liver. DTD enzyme activities were measured in tumour extracts using 2,6-dichlorophenolindophenol (DCPIP) and NADH as substrates; cytochrome P450 reductase or cytochrome b5 reductase activities were assessed with cytochrome c and NADPH or NADH respectively. DTD activity was highest in non-small-cell lung (NSCLC) tumours (mean 123 nmol DCPIP min(-1) mg(-1)), followed by colon carcinoma (mean 75 nmol min(-1) mg(-1)) and squamous cell carcinoma of the head and neck (6-fold lower than NSCLC). DTD activity was very low in normal liver and normal lung (4-6 nmol min(-1) mg(-1)), while the levels in normal colon mucosa or normal mucosa of the head and neck region were in the same range as the corresponding tumours. The levels of the two other reductive enzymes, cytochrome P450 reductase (CP450R) and cytochrome b5 reductase (Cb5R), were 5 to 25-fold lower than those of DTD in all the tissues, except for normal liver, in which DTD was 2 to 4-fold lower. The degree of variation found for DTD (range 4-250 nmol min(-1) mg(-1)), was not observed for these enzymes (CP450R, 0.8-7.8 nmol cytochrome c min(-1) mg(-1); Cb5R, 3.5-27.6 nmol min(-1) mg(-1)). It is anticipated that NSCLC patients are more likely to respond to EO9 and other bioreductive agents, owing to the high levels of the activating enzyme in this tumour type. To prove that this assay has predictive value we need to study these enzyme levels in tumour samples obtained from patients on clinical studies with bioreductive agents.

Original languageEnglish
Pages (from-to)917-921
Number of pages5
JournalBritish Jounal of Cancer
Volume72
Issue number4
Publication statusPublished - Oct-1995

Keywords

  • DT-DIAPHORASE
  • HEAD AND NECK SQUAMOUS CELL CARCINOMA
  • CYTOCHROME B5 REDUCTASE
  • CYTOCHROME P450 REDUCTASE
  • BIOREDUCTIVE AGENTS
  • EO9
  • MITOMYCIN-C
  • TUMOR-CELLS
  • METABOLISM
  • EXPRESSION
  • MECHANISMS
  • ACTIVATION
  • REDUCTASE
  • CARCINOMA
  • NAD(P)H
  • DRUGS

Cite this